Clinical trials: Transfusions
Thalassemia
Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO
Patients have severe beta-thalassemia or one of the thalassemia variants. Thalassemia is a hereditary disease in which the bone marrow produces abnormal red blood cells that have a shorter life span than normal red blood cells.
- Trial name
- THALLO (NCT00578292)
- Testing
- Busulfan, Fludarabine, Campath 1H
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor College of Medicine
Anemia
Mortality After Transfusion of Ever-pregnant Donor Red Blood Cells
The MATER study is an observational cohort study on first ever transfusion recipients in six hospitals in the Netherlands, with information collected on both donor and patient characteristics.
- Trial name
- MATER (NCT06176105)
- Where
- Netherlands
- Volunteers
- 101,000 people, healthy volunteers welcome
- Sponsor
- Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
Twin Twin Transfusion Syndrome
Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome
The investigators hypothesize that treatment of twin-twin transfusion syndrome (TTTS) using sequential laser photocoagulation of communicating vessels (SQLPCV) over the predominant method, selective laser photocoagulation of…
- Trial name
- NCT02122328
- Testing
- Sequential laser photocoagulation of communicating vessels., Selective laser photocoagulation of communicating vessels
- Where
- United States
- Volunteers
- 642 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alpha Thalassemia Major, Hemoglobinopathy; With Thalassemia
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
The investigators aims to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with alpha-thalassemia major performed at the time of in utero transfusion of red blood cells.
- Conditions
- Alpha Thalassemia Major, Hemoglobinopathy; With Thalassemia, Hemoglobinopathies, Fetal Anemia
- Trial name
- NCT02986698
- Testing
- in utero hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Transfusion-dependent Anemia
Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
This was a randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance and change in serum ferritin of a deferasirox granule formulation and a deferasirox dispersible tablet (DT) formulation in…
- Trial name
- NCT02435212
- Testing
- Deferasirox granule formulation, Deferasirox DT formulation
- Where
- 43 sites in United States, Belgium and 15 more
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Iron Overload
Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
This study will evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed be deferasirox monotherapy in patients with severe iron overload due to chronic blood transfusions.
- Trial name
- HYPERION (NCT01254227)
- Testing
- Deferasirox and Deferoxamine
- Where
- 15 sites in Canada, Egypt and 6 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Disease
Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization
Sickle cell patients have a high prevalence of alloimmunization. This high rate of alloimmunization can be partially explained by the existence of an antigenic difference between the predominantly Caucasian donor population and…
- Trial name
- NCT03405402
- Testing
- Blood sampling
- Where
- 2 sites in Belgium
- Volunteers
- 173 people
- Sponsor
- Hanane EL KENZ
Chronic Iron Overload Due to Transfusion-dependant Anemias
Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Assessed the new film-coated tablet formulation to the currently approved dispersible tablet formulation with regards to overall safety, Gastrointestinal (GI) tolerability, palatability, satisfaction and compliance
- Trial name
- NCT02125877
- Testing
- Deferasirox dispersible tablet, Defearisox film-coated tablet
- Where
- 51 sites in United States, Argentina and 14 more
- Volunteers
- 173 people
- Sponsor
- Novartis Pharmaceuticals
Transfusional Iron Overload, Transfusional Hemosiderosis
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
This is a clinical research study in patients who have iron overload in the heart due to chronic blood transfusions. The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a…
- Trial name
- CORDELIA (NCT00600938)
- Testing
- Core Study: Deferasirox, Core Study: Deferoxamine, Extension: deferoxamine to deferasirox
- Where
- 21 sites in Canada, China and 9 more
- Volunteers
- 197 people
- Sponsor
- Novartis Pharmaceuticals
Sickle Cell Anemia, Stroke
Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial
The goal of this study is to determine the effectiveness of blood transfusion therapy for prevention of silent cerebral infarct (stroke) in children with sickle cell anemia.
- Trial name
- SIT (NCT00072761)
- Testing
- transfusion therapy
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Washington University School of Medicine
Congenital Heart Disease
Transfusion Strategies in Pediatric Cardiothoracic Surgery
The purpose of this study is to determine the best red blood cell(hemoglobin) level for infants and children following surgical repair of particular heart defects.
- Trial name
- NCT00350220
- Testing
- transfusion strategy, Low Hb transfusion group
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester
Sickle Cell Disease, Sickle Cell Trait
Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors
Bearers of the sickle cell allele (S) are currently eligible for blood donations in Belgium. As blood donors are not tested for this allele, their heterozygous status is unknown.
- Trial name
- NCT03405688
- Testing
- Blood sampling
- Where
- 2 sites in Belgium
- Volunteers
- 173 people
- Sponsor
- Hanane EL KENZ
Hematocrit Anemia, Acidosis
Placental Transfusion in the 'Natural' Delivery: Effect of Early and Late Umbilical Cord Clamping
The investigators conducted a randomized controlled trial (parallel group study with 1:1 randomisation) comparing early cord clamping (ECC, at 60 seconds) and delayed cord clamping (DCC, at 180 seconds) in 90 cases of 'normal'…
- Trial name
- NCT04459442
- Testing
- Umbilical cord clamping at birth.
- Where
- 3 sites in Italy
- Volunteers
- 90 people
- Sponsor
- Policlinico Abano Terme
β-thalassemia
A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector…
- Trial name
- NCT06465550
- Testing
- BD211
- Where
- 3 sites in China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Hepatitis, Viral, Human, Blood Transfusion
Natural History of Post-transfusion Non-A, Non-B Hepatitis
To compare the clinical, biochemical, and histological status of Non-A, Non-B post-transfusion hepatitis patients with that of patients who did not develop post-transfusion hepatitis.
- Conditions
- Hepatitis, Viral, Human, Blood Transfusion, Liver Diseases
- Trial name
- NCT00005306
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Compliance With Restrictive RBC Transfusion Guideline
Trial of Feedback on Blood Use
Trial of Feedback on Blood Use (TOFU) The TOFU study will represent the first attempt to rigorously assess the impact of audit-feedback on changing transfusion practice.
- Trial name
- TOFU (NCT02232568)
- Testing
- Feedback
- Where
- 5 sites in United States
- Volunteers
- 426 people
- Sponsor
- Brigham and Women's Hospital
Blood Transfusion, Haematology
Study on Patient Blood Management in Haematological Patients
The investigators noticed a variable prescription of blood components to haematological patients in the hospital. This study will analyze the prescription and administration of blood components to Haematological patients (pre…
- Trial name
- NCT03217370
- Testing
- education of guidelines
- Where
- Belgium
- Volunteers
- 700 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Anemia, Cooley's, Beta-Thalassemia
Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America.
- Conditions
- Anemia, Cooley's, Beta-Thalassemia, Hematologic Diseases, Thalassemia
- Trial name
- NCT00000623
- Testing
- Deferoxamine, Deferiprone, Arginine
- Where
- 5 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Carelon Research
Very Low Birth Weight Infant, Placental Transfusion
Extrauterine Placental Transfusion In Neonatal Resuscitation Of Very Low Birth Weight Infants
To investigate the effect of extrauterine placental transfusion (EPT) compared to delayed cord clamping (DCC) on the mean hematokrit on the first day of life in very low birth weight infants (VLBW) born by caesarian section.
- Conditions
- Very Low Birth Weight Infant, Placental Transfusion, Anemia
- Trial name
- EXPLAIN (NCT03916159)
- Testing
- Extrauterine placental transfusion (Intervention group), Delayed cord clamping (Control group)
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Universitätsklinikum Köln
Cytomegalovirus Disease
TT-CMV Observational Birth Cohort Study
The spread of viruses through transfusions is the cause of serious illness and death in recipients whose immune systems are unable to fight infection.
- Trial name
- TT-CMV (NCT00907686)
- Where
- 3 sites in United States
- Volunteers
- 600 people
- Sponsor
- Emory University